Project: Predictive BioMarker platform for (pre-)clinical immuno-oncology drug screening on liquid biopsies
| Acronym | PreBioM (Reference Number: 113736) |
| Duration | 01/03/2020 - 01/03/2023 |
| Project Topic | A predictive patient material-based in vitro profiling service for immune-oncology drug candidates will be delivered, to reduce attrition in clinical trials. Cancer and immune cells from liquid biopsies will be characterized by DNA sequencing and RNA profiling. Immunological markers on immune and cancer cells and in body fluids will be analyzed by flow cytometry. Co-culture assays and innovative in-cell target engagement assays will be developed and validated with novel IDO1 and TDO inhibitors. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 12 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Oncolines B.V. | Coordinator | Netherlands |
| 2 | Pangaea Oncology | Partner | Spain |
| 3 | Pelago Bioscience AB | Partner | Sweden |